|
1
|
Potratz J, Dirksen U, Jurgens H and Craft
A: Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol.
29:1–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berenson JR, Lichtenstein A, Porter L,
Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester
O, Kovacs MJ, Blacklock HA, Bell R, et al: Efficacy of pamidronate
in reducing skeletal events in patients with advanced multiple
myeloma. Myeloma Aredia Study Group. N Engl J Med. 22:488–493.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tassone P, Tagliaferri P, Viscomi C,
Palmieri C, Caraglia M, D’Alessandro A, Galea E, Goel A, Abbruzzese
A, Boland CR and Venuta S: Zoledronic acid induces
antiproliferative and apoptotic effects in human pancreatic cancer
cells in vitro. Br J Cancer. 88:1971–1978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Odri GA, Dumoucel S, Picarda G, Battaglia
S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre
O, Gouin F, Heymann D, et al: Zoledronic acid as a new adjuvant
therapeutic strategy for Ewing’s sarcoma patients. Cancer Res.
70:7610–7619. 2010.PubMed/NCBI
|
|
5
|
Zhou Z, Guan H, Duan X and Kleinerman ES:
Zoledronic acid inhibits primary bone tumor growth in Ewing
sarcoma. Cancer. 104:1713–1720. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morgan GJ, Davies FE, Gregory WM, Szubert
AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH and Child
JA: Effects of induction and maintenance plus long-term
bisphosphonates on bone disease in patients with multiple myeloma:
the Medical Research Council Myeloma IX Trial. Blood.
119:5374–5383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heymann D, Ory B, Blanchard F, Heymann MF,
Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F and Redini
F: Enhanced tumor regression and tissue repair when zoledronic acid
is combined with ifosfamide in rat osteosarcoma. Bone. 37:74–86.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aft R, Naughton M, Trinkaus K, Watson M,
Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K,
Herrmann V, Dietz J, et al: Effect of zoledronic acid on
disseminated tumour cells in women with locally advanced breast
cancer: an open label, randomised, phase 2 trial. Lancet Oncol.
11:421–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zarogoulidis K, Boutsikou E, Zarogoulidis
P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G,
Kanakis I and Karamanos NK: The impact of zoledronic acid therapy
in survival of lung cancer patients with bone metastasis. Int J
Cancer. 125:1705–1709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siddiqui T, Marsh RW, Allegra C, Whittaker
D, Scarborough M, Gibbs P, Zlotecki R, Reith JD and Drane W:
Effective salvage treatment of recurrent Ewing sarcoma utilizing
chemotherapy and zoledronic acid. Clin Adv Hematol Oncol.
8:499–504. 2010.PubMed/NCBI
|
|
11
|
Kalos M, Levine BL, Porter DL, Katz S,
Grupp SA, Bagg A and June CH: T cells with chimeric antigen
receptors have potent antitumor effects and can establish memory in
patients with advanced leukemia. Sci Transl Med. 3:95ra732011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho D, Shook DR, Shimasaki N, Chang YH,
Fujisaki H and Campana D: Cytotoxicity of activated natural killer
cells against pediatric solid tumors. Clin Cancer Res.
16:3901–3909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Begley J, Vo DD, Morris LF, Bruhn KW,
Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N and
Ribas A: Immunosensitization with a Bcl-2 small molecule inhibitor.
Cancer Immunol Immunother. 58:699–708. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boni A, Cogdill AP, Dang P, Udayakumar D,
Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher
DE, Tsao H and Wargo JA: Selective BRAFV600E inhibition enhances
T-cell recognition of melanoma without affecting lymphocyte
function. Cancer Res. 70:5213–5219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Finke JH, Rini B, Ireland J, Rayman P,
Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and
Bukowski R: Sunitinib reverses type-1 immune suppression and
decreases T-regulatory cells in renal cell carcinoma patients. Clin
Cancer Res. 14:6674–6682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Skov S, Pedersen MT, Andresen L, Straten
PT, Woetmann A and Odum N: Cancer cells become susceptible to
natural killer cell killing after exposure to histone deacetylase
inhibitors due to glycogen synthase kinase-3-dependent expression
of MHC class I-related chain A and B. Cancer Res. 65:11136–11145.
2005. View Article : Google Scholar
|
|
17
|
Berghuis D, Schilham MW, Vos HI, Santos
SJ, Kloess S, Buddingh EP, Egeler RM, Hogendoorn PC and Lankester
AC: Histone deacetylase inhibitors enhance expression of NKG2D
ligands in Ewing sarcoma and sensitize for natural killer
cell-mediated cytolysis. Clin Sarcoma Res. 2:82012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fraser CK, Blake SJ, Diener KR, Lyons AB,
Brown MP, Hughes TP and Hayball JD: Dasatinib inhibits recombinant
viral antigen-specific murine CD4+ and CD8+
T-cell responses and NK-cell cytolytic activity in vitro and in
vivo. Exp Hematol. 37:256–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rossi LE, Avila DE, Spallanzani RG, Ziblat
A, Fuertes MB, Lapyckyj L, Croci DO, Rabinovich GA, Domaica CI and
Zwirner NW: Histone deacetylase inhibitors impair NK cell viability
and effector functions through inhibition of activation and
receptor expression. J Leukoc Biol. 91:321–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mariani S, Muraro M, Pantaleoni F, Fiore
F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella
B, Bruno B, Bertieri R, et al: Effector gamma delta T cells and
tumor cells as immune targets of zoledronic acid in multiple
myeloma. Leukemia. 19:664–670. 2005.PubMed/NCBI
|
|
21
|
Bringmann A, Schmidt SM, Weck MM, Brauer
KM, von Schwarzenberg K, Werth D, Grünebach F and Brossart P:
Zoledronic acid inhibits the function of Toll-like receptor 4
ligand activated monocyte-derived dendritic cells. Leukemia.
21:732–738. 2007.PubMed/NCBI
|
|
22
|
Pecherstorfer M, Jilch R, Sauty A, Horn E,
Keck AV, Zimmer-Roth I and Thiebaud D: Effect of first treatment
with aminobisphosphonates pamidronate and ibandronate on
circulating lymphocyte subpopulations. J Bone Miner Res.
15:147–154. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liote F, Boval-Boizard B, Fritz P and
Kuntz D: Lymphocyte subsets in pamidronate-induced lymphopenia. Br
J Rheumatol. 34:993–995. 1995. View Article : Google Scholar
|
|
24
|
Nussbaumer O, Gruenbacher G, Gander H and
Thurnher M: DC-like cell-dependent activation of human natural
killer cells by the bisphosphonate zoledronic acid is regulated by
γδ T lymphocytes. Blood. 118:2743–2751. 2011.PubMed/NCBI
|
|
25
|
Ottaviano L, Schaefer KL, Gajewski M,
Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E,
Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, et al: Molecular
characterization of commonly used cell lines for bone tumor
research: a trans-European EuroBoNet effort. Genes Chromosomes
Cancer. 49:40–51. 2010.PubMed/NCBI
|
|
26
|
Imai C, Iwamoto S and Campana D: Genetic
modification of primary natural killer cells overcomes inhibitory
signals and induces specific killing of leukemic cells. Blood.
106:376–383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alter G, Malenfant JM and Altfeld M:
CD107a as a functional marker for the identification of natural
killer cell activity. J Immunol Methods. 294:15–22. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen T, Berenson J, Vescio R, Swift R,
Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran
H, Seaman J, et al: Pharmacokinetics and pharmacodynamics of
zoledronic acid in cancer patients with bone metastases. J Clin
Pharmacol. 42:1228–1236. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lopez-Verges S, Milush JM, Pandey S, York
VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF and Lanier LL:
CD57 defines a functionally distinct population of mature NK cells
in the human CD56dimCD16+ NK-cell subset.
Blood. 116:3865–3874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coleman RE, Winter MC, Cameron D, Bell R,
Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley
D, Burkinshaw R, Marshall SJ, et al: The effects of adding
zoledronic acid to neoadjuvant chemotherapy on tumour response:
exploratory evidence for direct anti-tumour activity in breast
cancer. Br J Cancer. 102:1099–1105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Sarikonda G, Puan KJ, Tanaka Y,
Feng J, Giner JL, Cao R, Monkkonen J, Oldfield E and Morita CT:
Indirect Stimulation of Human Vγ2Vδ2 T cells through alterations in
isoprenoid metabolism. J Immunol. 187:5099–5113. 2011.
|
|
32
|
Marcu-Malina V, Heijhuurs S, van Buuren M,
Hartkamp L, Strand S, Sebestyen Z, Scholten K, Martens A and Kuball
J: Redirecting αβ T cells against cancer cells by transfer of a
broadly tumor-reactive γδT-cell receptor. Blood. 118:50–59.
2011.
|
|
33
|
Maniar A, Zhang X, Lin W, Gastman BR,
Pauza CD, Strome SE and Chapoval AI: Human γδ T lymphocytes induce
robust NK cell-mediated antitumor cytotoxicity through CD137
engagement. Blood. 116:1726–1733. 2010.
|
|
34
|
Sarhan D, D’Arcy P, Wennerberg E, Liden M,
Hu J, Winqvist O, Rolny C and Lundqvist A: Activated monocytes
augment TRAIL-mediated cytotoxicity by human NK cells through
release of IFN-gamma. Eur J Immunol. Sep 19–2012.(Epub ahead of
print).
|
|
35
|
Fujisaki H, Kakuda H, Shimasaki N, Imai C,
Ma J, Lockey T, Eldridge P, Leung WH and Campana D: Expansion of
highly cytotoxic human natural killer cells for cancer cell
therapy. Cancer Res. 69:4010–4017. 2009. View Article : Google Scholar
|
|
36
|
Dowell AC, Oldham KA, Bhatt RI, Lee SP and
Searle PF: Long-term proliferation of functional human NK cells,
with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype,
induced by carcinoma cells co-expressing 4–1BBL and IL-12. Cancer
Immunol Immunother. 61:615–628. 2012.PubMed/NCBI
|
|
37
|
Verhoeven DH, de Hooge AS, Mooiman EC,
Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC,
Egeler RM, van Tol MJ, Schilham MW and Lankester AC: NK cells
recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1
receptor dependent pathways. Mol Immunol. 45:3917–3925. 2008.
View Article : Google Scholar : PubMed/NCBI
|
